ライフサイエンスコーパス: radiotracer

1 s shown promise as a prostate cancer imaging radiotracer.

2 sion tomography with (11)C-raclopride as the radiotracer.

3 racted uptake kinetics and is not an optimal radiotracer.

4 nd radiation exposure using a PSMA-targeting radiotracer.

5 field, from 60 to 90 min after injection of radiotracer.

6 ther studied to evaluate it as a PET imaging radiotracer.

7 6.2 d (range, 0-13 d) after injection of the radiotracer.

8 the sand patties as shown with a (35)SO4(2-) radiotracer.

9 limited by local retention of cell-effluxed radiotracer.

10 essed using (99m)Tc-linear duramycin control radiotracer.

11 ormed to assess beta-cell selectivity of the radiotracer.

12 a rise in hypoxia-mediated entrapment of the radiotracer.

13 d to human trials as a first-in-class HD PET radiotracer.

14 escribed herein was to identify such a novel radiotracer.

15 assessing the safety and tolerability of the radiotracer.

16 e calculated using the Youden index for each radiotracer.

17 ats to determine the in vivo distribution of radiotracer.

18 imaging time is 60 minutes post injection of radiotracer.

19 tive predictive value were reported for each radiotracer.

20 iver and spleen hampers their performance as radiotracers.

21 y expanding prospects for developing new PET radiotracers.

22 s that are not well revealed by conventional radiotracers.

23 lar in magnitude to many other (18)F-labeled radiotracers.

24 ct the clinical radiological safety of novel radiotracers.

25 2.5-fold increase over baseline for both PET radiotracers.

26 erformed to assess the bioequivalence of all radiotracers.

27 onvenient synthon for labeling potential PET radiotracers.

28 milar kinetic and binding profiles for the 2 radiotracers.

29 ating the in vivo behavior of antibody-based radiotracers.

30 essibility and short half-lives of perfusion radiotracers.

31 nts relative to healthy controls with 2 TSPO radiotracers.

32 nto humans will require exploring additional radiotracers.

33 arch to first-in-human studies for novel PET radiotracers.

34 on studies showed high tumor uptake for both radiotracers.

35 fic membrane antigen, and (18)F-fluciclovine radiotracers.

36 revealed a similar biodistribution for the 2 radiotracers.

37 earch subjects were imaged with experimental radiotracers.

38 nt in vitro studies suggested that the novel radiotracer 1-(2-(18)F-fluoroethyl)-l-tryptophan ((18)F-

39 umor uptake of fructose metabolism-targeting radiotracers 1-[(18)F]FDF, 6-[(18)F]FDF, and 1-[(18)F]FD

40 In this study, we evaluated the radiotracer (11)C-AS2471907 (3-(2-chlorophenyl)-4-(methy

41 We developed and evaluated the radiotracer (11)C-BMT-136088 (1-(4'-(3-methyl-4-(((1(R)-

42 This was a first-in-human study of the PET radiotracer (11)C-LSN3172176 for the muscarinic acetylch

43 te whether PET with the weak ABCB1 substrate radiotracer (11)C-metoclopramide can measure ABCB1 induc

44 We used the radiotracer [(11)C]DAA1106 (a ligand for TSPO) and posit

45 PET imaging using the second-generation TSPO radiotracer [(11)C]DPA-713 revealed a strong trend towar

46 phy (PET) imaging with the novel KOR agonist radiotracer [(11)C]EKAP.

47 D2/3 agonist positron emission tomography radiotracer [(11)C]N-propyl-norapomorphine ([(11)C]NPA)

48 PET) scanner with the second-generation TSPO radiotracer [(11)C]PBR28.

49 e, we set out to develop 2 novel KOR agonist radiotracers, (11)C-EKAP and (11)C-FEKAP.

50 this problem by identifying and describing a radiotracer, [11C]GV1-57, that appears to specifically l

51 Here, we have evaluated a PET radiotracer, [11C]GV1-57, that specifically binds mature

52 The PET radiotracer (18)F-(2S,4R)4-fluoroglutamine ((18)F-Gln) r

53 pite its widespread use in oncology, the PET radiotracer (18)F-FDG is ineffective for improving early

54 pite its widespread use in oncology, the PET radiotracer (18)F-FDG is ineffective for improving early

55 ced MRI, diffusion-weighted imaging, and the radiotracer (18)F-FDG.

56 The novel PET radiotracer (18)F-flubrobenguane could change the diagno

57 ate the role of the synthetic amino acid PET radiotracer (18)F-fluciclovine in modifying the defined

58 the method in a pig model for the long-lived radiotracer (18)F-Flurpiridaz with adenosine as a pharma

59 To prepare and evaluate a new radiotracer (18)F-IRS for molecular imaging mutant EGF R

60 ution pattern of the novel cardiac nerve PET radiotracer (18)F-LMI1195 in healthy rabbits.

61 hether tumor uptake of the novel LIP-sensing radiotracer (18)F-TRX aligns with tumor sensitivity to L

62 stem using the PKM2 gene with its associated radiotracer [(18)F]DASA-23.

63 T) imaging using the mGlu5 receptor-specific radiotracer [(18)F]FPEB during early and extended alcoho

64 The respective radiotracer [(18)F]PSMA-1007 was translated into the cli

65 s to evaluate if the recently introduced PET radiotracer [(18)F]tetrafluoroborate ([(18)F]BF4(-)) is

66 y artery specimens, the non-invasive imaging radiotracer, (18)F-fluoride, was highly selective for hy

67 ther the in vivo characteristics of our lead radiotracer, (18)F-LW223, are suitable for clinical tran

68 )F positron emission tomography (PET) DREADD radiotracer, [(18)F]JHU37107.

69 We assessed the radiotracer 18F-AV-1451 with positron emission tomograph

70 Here, we show that a novel PET radiotracer, 2'-deoxy-2'-[18F]fluoro-9-beta-D-arabinofur

71 A mass balance method and a radiotracer, (32)P (as H3PO4), were used to investigate

72 lts for the novel estrogen receptor (ER) PET radiotracer 4-fluoro-11beta-methoxy-16alpha-(18)F-fluoro

73 This study developed the radiotracer (64)Cu-labeled anti-CD11b ((64)Cu-alphaCD11b

74 sing a targeted positron emission tomography radiotracer ((64)Cu-DOTA-ECL1i).

75 limitations, we evaluated a novel, sensitive radiotracer [(64)Cu]Cu-Bn-NOTA-hu14.18K322A to detect GD

76 Using the peptide radiotracer [64Cu]WL12 in vivo, we employed positron emi

77 The PET radiotracer (68)Ga-PSMA (prostate-specific membrane anti

78 The PET radiotracer (68)Ga-PSMA-HBED-CC ((68)Ga-PSMA-11) shows p

79 te-specific membrane antigen (PSMA)-targeted radiotracers (68)Ga/(177)Lu-PSMA-I&T and (99m)Tc-PSMA-I&

80 erformance of a positron emission tomography radiotracer ((68)Ga-DOTA [1,4,7,10-tetraazacyclododecane

81 Also, we report two (99m)Tc-radiotracers, (99m)Tc-AGA-1 and (99m)Tc-AGA-2, derived f

82 raphy-tandem mass spectrometry for measuring radiotracer A(m) and then the carrier in plasma sampled

83 One hour after injection of either radiotracer, a head-to-thigh static scan with a 2-min ac

84 prostatic lesion, similarly detected by both radiotracers, a second less intense positive focus was d

85 g time-activity curve from 0 to 80 min after radiotracer administration [AUC(lung)]) was 77% higher a

86 nd U87-MG tumors was observed at 20 min post radiotracer administration with SUV of 1.45 +/- 0.05 and

87 reased k (E,lung) by 20% after intratracheal radiotracer administration.

88 ide-treated mice at 15, 30, and 60 min after radiotracer administration.

89 ts revealed high intratumoral uptake of both radiotracers already 10 min after administration but a h

90 This radiotracer also identified lesions as small as 29 mm(3)

91 (99m)Tc-SP is a valid radiotracer alternative to (99m)Tc-SC for routine GES ex

92 eference perfusion marker (201)Tl for a dual-radiotracer analysis.

93 went PET/CT with (68)Ga-DOTA-E-[c(RGDfK)](2) radiotracer and blood-sample tests to quantify angiogene

94 as been recently introduced as a theranostic radiotracer and demonstrated high uptake into different

95 I, and PET/mpMR-wbMR) were compared for each radiotracer and each individual patient (for (18)F-FCH,

96 procedures, employee health, availability of radiotracers and other essential supplies, and availabil

97 ent/progression and the development of novel radiotracers and pharmaceuticals for clinical applicatio

98 is placed on MI without probes, MI based on radiotracers and small molecules, MI nano- and microsyst

99 optimization and performance with different radiotracers and time-of-flight imaging.

100 PET findings were compared between the 2 radiotracers and with reference-standard pathologic spec

101 ith [(11)C]FLB457, a dopamine D2/D3 receptor radiotracer, and positron emission tomography (PET).

102 gs; in 32 (30.8%), on the findings with both radiotracers; and in 50 (48.1%), on the (68)Ga-DOTATATE

103 are many, positron emission tomography (PET) radiotracers are still available only as research tools.

104 Radiotracers are widely used to track molecular processe

105 A radiotracer arterial input function (AIF) is often essen

106 ent to assess the prognostic utility of this radiotracer as a noninvasive imaging biomarker of plaque

107 This review summarizes the radiotracers as applied to imaging of bacterial infectio

108 includes physiologic biodistribution of the radiotracer, as well as conditions that engender false-p

109 particularly attractive precursors to these radiotracers, as they are readily available, inexpensive

110 mino acid fluxes via VRAC were quantified by radiotracer assays in cells challenged with hypoosmotic

111 We used an RNAi approach and radiotracer assays to explore which LRRC8 isoforms contr

112 on tomography (PET) scans with two different radiotracers at baseline prior to brexpiprazole administ

113 s can be inferred from imaging the change in radiotracer binding at D(2) receptors due to a pharmacol

114 This is feasible if radiotracer binding is measured when postchallenge DA le

115 ken from rats over 240 min after intravenous radiotracer bolus injection.

116 n) is a major radionuclide for labeling such radiotracers but is only readily available in high activ

117 anoparticle constructs have been utilized as radiotracers, but irrespective of the particle class, ra

118 ntually led to the discovery of the clinical radiotracer candidate [(11)C]MK-6884.

119 The influence of CBF and radiotracer clearance changes on amyloid-beta load estim

120 mulations showed a limited impact of CBF and radiotracer clearance changes on multilinear reference t

121 re performed to assess the effect of CBF and radiotracer clearance changes on SUVRs and noninvasive k

122 A blood radioassay indicated that radiotracer clearance from blood and plasma was initiall

123 ond, to assess the impact of CBF changes and radiotracer clearance on SUVRs and noninvasive kinetic m

124 d by changes in cerebral blood flow (CBF) or radiotracer clearance.

125 positron emission tomography (PET) using D2R radiotracers combined with psychostimulant challenge.

126 The accuracy of (177)Lu radiotracer concentration measurements using quantitativ

127 monstrating the importance of accounting for radiotracer concentrations in plasma.

128 rm previous PET studies reporting lower TSPO radiotracer concentrations in the brain (measured as SUV

129 approximately 20% of in vivo urinary bladder radiotracer concentrations.

130 In addition, both radiotracers correlated well (Kendall's Tau (tau) coeffi

131 positive osteosarcoma sites with a novel PET radiotracer could significantly impact anti-GD2 immunoth

132 ined using polar distributions of normalized radiotracer counts, hypoperfusion defects, and hypoperfu

133 maged with (18)F-FAC PET to quantify if this radiotracer crosses the blood-brain barrier (BBB).

134 A significant and profound reduction in the radiotracer delivery parameter K (1) after TACE was obse

135 Injection of free radiotracer demonstrated a faster clearance of (18)F-FLT

136 Here we report four novel (99m)Tc-labeled radiotracers derived from a highly selective competitive

137 Radiotracer design modifications included chelate, glyco

138 article considers their potential impact on radiotracer design.

139 (18)F-T807 is a PET radiotracer developed for imaging tau protein aggregates

140 (123)I-CLINDE is a radiotracer developed for SPECT and targets the 18-kDa t

141 8)F-positron emission tomography ((18)F-PET) radiotracer development emphasizing sensitivity to chang

142 the opportunities for medicinal chemists in radiotracer development for bacterial infections, with a

143 C-H bonds, which limits advancements in PET radiotracer development.

144 ligands with affinity for the same site, in radiotracer development.

145 slight but significant discrepant transmural radiotracer distribution pattern of (201)Tl in compariso

146 metric maps of tumor hypoxia, perfusion, and radiotracer distribution volume.

147 ucted to yield high-resolution images of the radiotracer distribution.

148 of radioactivity to total mass; Bq/mol) of a radiotracer dose and the time-course of carrier concentr

149 The groups did not differ in injected radiotracer dose or body weight, which were used to calc

150 d even by SPECT with the currently available radiotracers (e.g., metaiodobenzylguanidine [MIBG]).

151 ability to bind cell surface PSMA, and both radiotracers exhibited selective uptake into PSMA-positi

152 According to our radiotracer experiments, it takes the sheath-water bacte

153 Notably two of the radiotracers, FAPI-21 and -46, displayed substantially i

154 their activities were determined by fructose radiotracer flux.

155 the initial competition phase between DA and radiotracer for binding to D2R.

156 tic challenges associated with accessing the radiotracer for clinical use; these stem from the need t

157 mycin holds promise as a noninvasive imaging radiotracer for early treatment evaluation in the clinic

158 wo sites and validated for production of the radiotracer for human use.

159 develop and evaluate preclinically a (68)Ga radiotracer for imaging PSMA expression that could be ra

160 amine ((18)F-FGln) is an investigational PET radiotracer for imaging tumor glutamine flux and metabol

161 usion: (68)Ga-FAPI-04 represents a promising radiotracer for in vivo imaging of post-MI fibroblast ac

162 acterial accumulation, make it an attractive radiotracer for infection imaging in clinical practice.

163 2-(18)F-FEtOH is a novel (18)F-based radiotracer for investigating tumor perfusion with PET i

164 his study was development of an improved PET radiotracer for measuring x(C) (-) activity with increas

165 onclusion: (18)F-hGTS13-isomer2 is a new PET radiotracer for molecular imaging of x(C) (-) activity t

166 use as a positron emission tomography (PET) radiotracer for noninvasive detection of lung inflammati

167 Conclusion:(11)C-sarcosine is a novel radiotracer for PATs and shows initial utility for prost

168 ates and appears to be the first appropriate radiotracer for PET imaging of human M(1) AChR.

169 (68)Ga-pentixafor is a radiotracer for PET that binds with nanomolar affinity t

170 Radiocaine, an F-18 radiotracer for positron emission tomography (PET), is t

171 PET)/computed tomography (CT) is a promising radiotracer for quantitative assessment of bone metastas

172 8)F-LY2459989 appears to be an excellent PET radiotracer for the imaging and quantification of the KO

173 ing bifunctional HBED chelators are powerful radiotracers for cancer diagnosis and therapy.

174 the translation of small engineered protein radiotracers for imaging human immune checkpoints.

175 eviously developed several (11)C-labeled PET radiotracers for KOR imaging in humans.

176 This process has potential for preparing new radiotracers for molecular imaging with positron emissio

177 11)C-GR103545 and antagonist (11)C-LY2795050 radiotracers for PET imaging of KOR in humans.

178 Current radiotracers for PET of hNIS expression are limited to (

179 The availability of M(1)-selective radiotracers for PET will help in developing therapeutic

180 Many PSMA analog radiotracers for PET/CT prostate cancer staging have bee

181 F]-labeled aryl fluorides are widely used as radiotracers for positron emission tomography (PET) imag

182 ractive platforms for building multimodality radiotracers for SPECT/MRI and PET/MRI.

183 tudy were to screen novel, fluorinated, TSPO radiotracers for susceptibility to the rs6971 genetic po

184 te-specific membrane antigen (PSMA)-targeted radiotracers, for example, (99m)Tc-labeled PSMA tracer a

185 This radiotracer has achieved good results in multiple clinic

186 namic, kinetic, and metabolic stability of a radiotracer, has attracted much attention but the chemis

187 prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imag

188 The normative values for both radiotracers have also been determined for the healthy m

189 dditional studies with experimental research radiotracers illustrated the benefits from the combinati

190 everal biologically and clinically important radiotracers illustrates the potentials of this methodol

191 ed specific accumulation of the carbohydrate radiotracer in galectin-1-overexpressing UMUC3 orthotopi

192 equent BBB opening did not lead to uptake of radiotracer in the brain.

193 inutes, there is physiologic accumulation of radiotracer in the urinary bladder which may cause some

194 Uptake of the radiotracer in tumors was concordant with levels of DLL3

195 ld trametinib, confirming specificity of the radiotracer in vitro and in vivo.

196 aimed to compare the emptying rates of both radiotracers in a prospective, randomized cross-over tri

197 We will also present several new radiotracers in development, with an emphasis on probes

198 characteristics of selected hexose-based PET radiotracers in murine BC model EMT6.

199 ence using fluciclovine versus PSMA-targeted radiotracers in patients with a prostate-specific antige

200 ble effects due to high accumulation of PSMA radiotracers in salivary glands and kidneys.

201 ogen-specific imaging and the application of radiotracers in understanding drug pharmacokinetics as w

202 Important PCa radiotracers include (68)Ga-prostate-specific membrane a

203 A radiotracer incorporating this linker with a dual triflu

204 In vitro, radiotracer incorporation and efflux was similar with no

205 red in biodistribution studies 285 min after radiotracer injection (percentage injected dose per gram

206 termined in plasma and brain at 15 min after radiotracer injection.

207 rse of carrier concentration in plasma after radiotracer injection.

208 -FAPI-46 PET/CT scans at 3 time points after radiotracer injection: 10 min, 1 h, and 3 h.

209 PET/CT scans at three time points following radiotracer injection: 10 minutes, 1 hour, and 3 hours.

210 mated by MGH2 were nearly the same for the 2-radiotracer injections (mean difference: 0.067+/-0.070 m

211 PET/CT-guided biopsy using (89)Zr-labeled radiotracers is safe and effective without tracer reinje

212 hese studies, performed with D2/3 antagonist radiotracers, is the failure to provide information abou

213 ensitive, positron emission tomography (PET) radiotracer known as 4-[(18)F]fluorobenzyl-triphenylphos

214 For radiotracers labeled with carbon-11 (t(1/2) = 20.4 min),

215 success of PC treatment with PSMA inhibitor radiotracers leads to several questions from the basic r

216 ng both [(11)C]DASB and [(18)F]MPPF, two PET radiotracers, marking the serotonin transporter and the

217 Thus, a LPA1 PET radiotracer may be useful for studying lung fibrosis or

218 after diagnostic PET/CT using (89)Zr-labeled radiotracers (mean dose, 180 MBq; range, 126-189 MBq) ta

219 sing tetramethylammonium, as well as earlier radiotracer methods, have shown that the extracellular s

220 duced an early uptake of (99m)Tc-NC100692 (a radiotracer of angiogenesis) and improved perfusion, as

221 We used (123)I-iodobenzovesamicol, a SPECT radiotracer of the vesicular acetylcholine transporter,

222 and ischemia, rate-pressure product, type of radiotracer or stress agent used, and revascularization

223 support the use of CLI for the evaluation of radiotracer performance.

224 e feasibility of within-suite (89)Zr-labeled radiotracer PET/CT-guided biopsy performed without reinj

225 Methods: Radiotracer preparation followed the manufacturer's indi

226 tion to automated radiosynthesis for routine radiotracer production in human clinical imaging.

227 herefore well suited to be automated for PET radiotracer production.

228 was performed within a PET/CT suite without radiotracer reinjection.

229 cells in the tumor, or the perfusion of the radiotracer remains unknown.

230 The development of antibody-based radiotracers requires extensive characterization of thei

231 we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimatio

232 retention of a system x(c) (-)-specific PET radiotracer, (S)-4-(3-[(18)F]fluoropropyl)-L-glutamic ac

233 cquired after a single administration of the radiotracer: shortly after injection as well as approxim

234 n the stomach, kidneys, and gallbladder, the radiotracer showed a rapid initial uptake, which cleared

235 Using PET imaging with a radiotracer specific for the serotonin transporter (5-HT

236 histology of the human substantia nigra and radiotracer studies of the human striatum.

237 New radiotracers, such as (68)Ga-DOTA-E-[c(RGDfK)](2), that

238 ard method will gain wide acceptance for PET radiotracer syntheses across the radiochemistry communit

239 In recent years, several radiotracers targeting the prostate-specific membrane an

240 Radiotracer techniques were used to perform measurements

241 prostate-specific membrane antigen-targeted radiotracers than fluciclovine for prostate specific ant

242 cid ((18)F-fluciclovine) is a leucine analog radiotracer that depicts amino acid transport into cells

243 -7-(11)C-methylpurine ((11)C-BMP), a prodrug radiotracer that is intracellularly conjugated with glut

244 binofuranosyl) cytosine ((18)F-FAC) is a PET radiotracer that measures deoxyribonucleoside salvage an

245 -arabinofuranosyl-adenine ((18)F-CFA), a PET radiotracer that measures deoxyribonucleoside salvage in

246 d that (125)I-iodo-DPA-713, a small-molecule radiotracer that specifically targets macrophages, could

247 ions to study the brain has been the lack of radiotracers that can identify and measure specific type

248 e potential to become a prototype for future radiotracers that can identify other neuronal cell types

249 nvolved in cognition and behaviors, by using radiotracers that detect relevant biological reactions.

250 Radiotracers that leverage other hallmarks of cancer or

251 itron emission tomography (PET) imaging with radiotracers that target translocator protein 18 kDa (TS

252 anced molecular imaging techniques and novel radiotracers to achieve better outcomes for patients wit

253 linical doses to ease translation of new PET radiotracers to first-in-human studies.

254 Positron emission tomography (PET) uses radiotracers to quantify important biochemical parameter

255 PET requires biochemically selective radiotracers to realize full potential.

256 tomography (PET) analogue of the (123)I-mIBG radiotracer, to quantify NET-1 expression levels in mous

257 We estimated the rate constants for radiotracer transfer across the BRB (K1, k2) and total r

258 o correct the binding potential for impaired radiotracer transfer from plasma to tissue (BP(TC)).

259 At day 7 post-AAA induction, the radiotracer uptake (standardized uptake value [SUV]=0.91

260 Radiotracer uptake and efflux in hNIS-transduced HCT116-

261 rtery, and assessed the relationship between radiotracer uptake and plaque phenotype or predicted car

262 At 14 days post-AAA induction, radiotracer uptake by either group did not significantly

263 administration of ICM led to a reduction in radiotracer uptake by the thyroid, accompanied by a dram

264 consensus central review identified foci of radiotracer uptake consistent with sites of PCa.

265 The localization of radiotracer uptake in AAA was verified with high-resolut

266 There was low variability in radiotracer uptake in all major organs for the mouse hot

267 y gland, kidney, and other normal-organ PSMA radiotracer uptake in human subjects, using (18)F-DCFPyL

268 the first time, the detection of [(18)F]FDG radiotracer uptake in single cells through fluorescence

269 However, significantly lower radiotracer uptake in terms of SUL(mean), SUL(peak), and

270 ents with breast cancer; however, incidental radiotracer uptake in the breasts can be observed in pat

271 Quantification of PSMA radiotracer uptake is desired as it enables reliable int

272 In the salivary glands, neither radiotracer uptake nor NIS protein expression was affect

273 g and straight walking, performed during the radiotracer uptake period.

274 SPECT/CT images for in vivo urinary bladder radiotracer uptake using quantitative software.

275 In addition, radiotracer uptake was evaluated in 3 breast cancer mode

276 Radiotracer uptake was validated ex vivo by gamma-counti

277 orate on day 10, to ascertain specificity of radiotracer uptake.

278 ucing costs and maximizing the efficiency of radiotracer use when compared with scans performed with

279 ceptors and SERT was not detectable with the radiotracers used for these targets.

280 sed PET dosimetry data of six (18)F-labelled radiotracers using preclinical dosimetry models, differe

281 MBq ( approximately 10 mug) of an engineered radiotracer variant and imaged.

282 Six HAC-PD1 radiotracer variants were developed and used in preclini

283 de strong preclinical evidence that this new radiotracer warrants further studies that may lead to a

284 In the first 2 parts, the radiotracer was administered using a bolus-plus-infusion

285 The radiotracer was evaluated in vitro and in vivo.

286 In naive mice, the radiotracer was quickly cleared from the blood and displ

287 The uptake of all radiotracers was higher in MZ-CRC-1 tumors than in A431-

288 th the recent development of in vivo tau PET radiotracers, we show that Abeta and tau are associated

289 tumor targeting and pharmacokinetics of the radiotracers were also evaluated in HCC827, H1975, H358

290 vity of approximately 14.0 MBq nmol(-1) Both radiotracers were immunoreactive and stable in human ser

291 beling by (19)F-(18)F isotopic exchange, the radiotracers were injected in mice bearing LNCaP xenogra

292 Four existing and two novel PET radiotracers were investigated: [(18)F]FDG, [(18)F]AlF-N

293 Radiotracers were purified by using size-exclusion metho

294 Methods: Novel quinoline-based radiotracers were synthesized by organic chemistry and e

295 hymidine ((18)F-FLT); a clinically available radiotracer which we hypothesise will result in minimal

296 Patients received 174 +/- 28 MBq of the radiotracer, which was well tolerated in all patients ov

297 25 novel radioligands that aims to identify radiotracers with optimal pharmacokinetic and dosimetric

298 The use of synaptic vesicle glycoprotein 2A radiotracers with PET imaging could provide a way to mea

299 conducted, with the eventual replacement of radiotracers with stable isotopically labeled ones, even

300 d identified [(11)C]OCM-44 as our lead GSK-3 radiotracer, with optimized brain uptake by PET imaging